SCHEMBL2178758

SCHEMBL2178758

COCCCOc1cc(/C=C/c2cccc(OC)c2OC)cc(C(=O)Nc2nccs2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.53
MAPT P10636 2/20 0.53
BRD4 O60885 1/20 0.53
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
ALDH1A1 P00352 3/20 0.52
HPGD P15428 2/20 0.52
GAA P10253 2/20 0.52
KDM4E B2RXH2 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
RAB9A P51151 6/20 0.48
NPC1 O15118 5/20 0.48
MAPK1 P28482 1/20 0.48
GCK P35557 6/20 0.46
TSHR P16473 1/20 0.45
ADRB2 P07550 1/20 0.45
HTT P42858 1/20 0.45
LMNA P02545 1/20 0.44
KCNH2 Q12809 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2178336 0.93 GCK (0.53) SMN1; SMN2MAPTBRD4MEN1KMT2A
SCHEMBL2176556 0.89 SMN1; SMN2 (0.52) SMN1; SMN2MAPTBRD4MEN1KMT2A
SCHEMBL2176564 0.89 SMN1; SMN2 (0.52) SMN1; SMN2MAPTBRD4MEN1KMT2A
SCHEMBL2178760 0.89 GCK (0.60) SMN1; SMN2MAPTBRD4MEN1KMT2A
SCHEMBL2179757 0.87 GCK (0.53) SMN1; SMN2MAPTBRD4MEN1KMT2A
SCHEMBL2176342 0.86 NPC1 (0.48) SMN1; SMN2MAPTBRD4MEN1KMT2A
SCHEMBL2179607 0.85 GCK (0.46) GCK
SCHEMBL2177526 0.84 GCK (0.54) SMN1; SMN2MAPTBRD4ALDH1A1HPGD
SCHEMBL2177785 0.84 GCK (0.53) SMN1; SMN2MAPTBRD4ALDH1A1HPGD
SCHEMBL2175779 0.84 GCK (0.52) SMN1; SMN2MAPTBRD4ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178765-A1 NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2012-07-12 US claimed
WO-2011081280-A2 NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2011-07-07 WO claimed
US-20120178765-A1 NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2012-07-12 US disclosed
WO-2011081280-A2 NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178765-A1 NOVEL GLUCOKINASE ACTIVATORS AND PROCESSES FOR THE PREPARATION THEREOF GCK, GCKR, HK1 SMN1; SMN2 4303/4885MAPT 3236/4885BRD4 2256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.